Ceramide–Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments

Mika Hilvo, Angelika Witoslawska, Mitja Lääperi, Antti Jylhä, Leo-Pekka Lyytikäinen, Hannu Päivä, Jari Laurikka, Winfried März, Pekka J. Karhunen, Terho Lehtimäki, Reijo Laaksonen

Open source

DOI: 10.1097/fjc.0000000000001817
Published: 2026-07-20
Container: Journal of Cardiovascular Pharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/fjc.0000000000001817,
  title = {Ceramide–Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments},
  author = {Mika Hilvo and Angelika Witoslawska and Mitja Lääperi and Antti Jylhä and Leo-Pekka Lyytikäinen and Hannu Päivä and Jari Laurikka and Winfried März and Pekka J. Karhunen and Terho Lehtimäki and Reijo Laaksonen},
  year = {2026},
  journal = {Journal of Cardiovascular Pharmacology},
  doi = {10.1097/fjc.0000000000001817},
  url = {https://doi.org/10.1097/fjc.0000000000001817}
}

RIS

TY  - JOUR
TI  - Ceramide–Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments
AU  - Mika Hilvo
AU  - Angelika Witoslawska
AU  - Mitja Lääperi
AU  - Antti Jylhä
AU  - Leo-Pekka Lyytikäinen
AU  - Hannu Päivä
AU  - Jari Laurikka
AU  - Winfried März
AU  - Pekka J. Karhunen
AU  - Terho Lehtimäki
AU  - Reijo Laaksonen
PY  - 2026
JO  - Journal of Cardiovascular Pharmacology
DO  - 10.1097/fjc.0000000000001817
UR  - https://doi.org/10.1097/fjc.0000000000001817
ER  -

APA

Hilvo, M., Witoslawska, A., Lääperi, M., Jylhä, A., Lyytikäinen, L., Päivä, H., Laurikka, J., März, W., Karhunen, P. J., Lehtimäki, T., & Laaksonen, R. (2026). Ceramide–Phospholipid Risk Score Associates With Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000001817

Source records

crossref · retrieved 2026-09-27T07:07:58.484Z